Physicians' Academy for Cardiovascular Education

Progressive CAD despite low LDL-C, an elusive disease?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema

Video navigation menu

  • What are the treatment options in patients with progressive CAD? 00:18
  • Which patients do progress more, despite profound LDL-c lowering? 02:14
  • Does it matter how LDL-c is lowered? 03:35
  • How important is the duration of exposure to treatment, is the effect cumulative? 04:14

Educational information

This video was recorded during an expert meeting among cardiologists and internists, focussing on the topic of 'LDL-c & PCSK9 inhibition in high CV risk patients - Balancing Science, Guidelines and Daily Cardiology Practice'.

The objectives of the meeting were to:

Other topics covered in this series

Other lectures part of this educational series are:

Faculty

Prof. Kausik Ray, cardiologist, Imperial College London, United Kingdom

Prof. Wouter Jukema, cardiologist, Leiden University Medical Center, Leiden, The Netherlands

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Funding for the Expert Meeting was provided by an unrestricted educational grant from Amgen. The sponsor did not attend and influence the video recording.

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.

Share this page with your colleagues and friends: